Harrow HROW Stock
Harrow Price Chart
Harrow HROW Financial and Trading Overview
| Harrow stock price | 12.65 USD |
| Previous Close | 19.5 USD |
| Open | 19.5 USD |
| Bid | 0 USD x 1000 |
| Ask | 0 USD x 900 |
| Day's Range | 18.76 - 20.21 USD |
| 52 Week Range | 6.14 - 28.25 USD |
| Volume | 490.47K USD |
| Avg. Volume | 442.61K USD |
| Market Cap | 568.4M USD |
| Beta (5Y Monthly) | 0.195422 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.75 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.13 USD |
HROW Valuation Measures
| Enterprise Value | 736.76M USD |
| Trailing P/E | N/A |
| Forward P/E | 21.689655 |
| PEG Ratio (5 yr expected) | -3.18 |
| Price/Sales (ttm) | 6.139711 |
| Price/Book (mrq) | 25.920332 |
| Enterprise Value/Revenue | 7.958 |
| Enterprise Value/EBITDA | 133.689 |
Trading Information
Harrow Stock Price History
| Beta (5Y Monthly) | 0.195422 |
| 52-Week Change | 188.09% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 28.25 USD |
| 52 Week Low | 6.14 USD |
| 50-Day Moving Average | 22.76 USD |
| 200-Day Moving Average | 16 USD |
HROW Share Statistics
| Avg. Volume (3 month) | 442.61K USD |
| Avg. Daily Volume (10-Days) | 304.81K USD |
| Shares Outstanding | 30.12M |
| Float | 24.27M |
| Short Ratio | 4.78 |
| % Held by Insiders | 8.02% |
| % Held by Institutions | 63.69% |
| Shares Short | 2.89M |
| Short % of Float | 11.89% |
| Short % of Shares Outstanding | 9.58% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:5 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -19.75% |
| Operating Margin (ttm) | 1.11% |
| Gross Margin | 70.08% |
| EBITDA Margin | 5.95% |
Management Effectiveness
| Return on Assets (ttm) | 0.40% |
| Return on Equity (ttm) | -117.0099% |
Income Statement
| Revenue (ttm) | 92.58M USD |
| Revenue Per Share (ttm) | 3.28 USD |
| Quarterly Revenue Growth (yoy) | 18.00% |
| Gross Profit (ttm) | 63.21M USD |
| EBITDA | 5.51M USD |
| Net Income Avi to Common (ttm) | -18291000 USD |
| Diluted EPS (ttm) | -0.61 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 27M USD |
| Total Cash Per Share (mrq) | 0.9 USD |
| Total Debt (mrq) | 176.73M USD |
| Total Debt/Equity (mrq) | 820.94 USD |
| Current Ratio (mrq) | 2.919 |
| Book Value Per Share (mrq) | 0.728 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -7476000 USD |
| Levered Free Cash Flow (ttm) | -134511872 USD |
Profile of Harrow
| Country | United States |
| State | TN |
| City | Nashville |
| Address | 102 Woodmont Boulevard |
| ZIP | 37205 |
| Phone | 615 733 4730 |
| Website | https://www.harrowinc.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 217 |
Harrow Health, Inc., an eyecare pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies. The company offers ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic medicines, including IOPIDINE and MOXEZA; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection drug candidate. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Q&A For Harrow Stock
What is a current HROW stock price?
Harrow HROW stock price today per share is 12.65 USD.
How to purchase Harrow stock?
You can buy HROW shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Harrow?
The stock symbol or ticker of Harrow is HROW.
Which industry does the Harrow company belong to?
The Harrow industry is Drug Manufacturers-Specialty & Generic.
How many shares does Harrow have in circulation?
The max supply of Harrow shares is 35.36M.
What is Harrow Price to Earnings Ratio (PE Ratio)?
Harrow PE Ratio is now.
What was Harrow earnings per share over the trailing 12 months (TTM)?
Harrow EPS is -0.75 USD over the trailing 12 months.
Which sector does the Harrow company belong to?
The Harrow sector is Healthcare.
Harrow HROW included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}